文献速递妇科

传统高剂量率腔内近距离放疗联合辅助施源器引导调强放疗推量治疗大体积宫颈肿瘤患者的临床结局

Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour.
PubMed 文献 · BJOG · 2022-11-13

回顾性队列研究纳入76例FIGO IIB-IVA期大体积(HR-CTV>40 ml)宫颈癌患者,接受同步放化疗后行腔内近距离放疗联合施源器引导调强放疗推量。中位随访85个月,5年局部无复发生存率87.6%、无病生存率70.9%、肿瘤特异生存率76.3%,3级晚期胃肠及泌尿毒性分别为3.9%和5.2%,无4级毒性。

要点

  • 大体积宫颈癌同步放化疗后采用腔内近距离放疗联合辅助调强放疗推量,5年局部无复发生存率达87.6%。
  • 3级晚期胃肠道和泌尿毒性分别为3.9%和5.2%,未观察到4级急性或晚期毒性。
  • HR-CTV的D90为88.7±3.6 Gy,膀胱、直肠D2cc分别为71.8±3.8和64.6±4.9 Gy。

核心结论

  • 腔内近距离放疗联合施源器引导辅助调强放疗推量对大体积残留宫颈肿瘤实现了优异的局部控制和总生存,且毒性低。

研究设计与样本

  • 回顾性队列研究,纳入2010年6月至2016年10月四川省肿瘤医院·研究所76例局部晚期宫颈癌(FIGO IIB-IVA期)患者。
  • 入组标准为近距离放疗时高危临床靶区体积(HR-CTV)大于40 ml。
  • 所有患者接受同步放化疗后行腔内近距离放疗联合调强放疗推量(IC/IMRT)。
  • 体外放疗为45 Gy分25次,在IC/IMRT前给予顺铂化疗。
  • IMRT计划基于ICBT计划用逆向剂量优化工具优化,采用七野机架角度IMRT计划以避免热点。

主要发现

  • 近距离放疗时平均HR-CTV为65.8±23.6 ml。
  • HR-CTV和IR-CTV的D90分别为88.7±3.6 Gy和78.1±2.5 Gy。
  • 膀胱、直肠、乙状结肠和小肠的D2cc分别为71.8±3.8、64.6±4.9、63.9±5.3和56.7±8.7 Gy。
  • 中位随访85个月(47.9-124.2个月)。
  • 5年局部无复发生存率、转移无复发生存率、无病生存率和肿瘤特异生存率分别为87.6%、82.4%、70.9%和76.3%。

临床怎么用

  • 作者认为,对于大体积残留宫颈肿瘤,腔内近距离放疗联合施源器引导辅助调强放疗推量可达到优异的局部控制和总生存,且毒性低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical outcomes and toxicity in patients with locally advanced cervical cancer treated with supplementary applicator guided-intensity modulated radiation therapy (IMRT) based on conventional intracavitary brachytherapy (IC/IMRT). DESIGN: A retrospective cohort study. SETTING: Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, China. POPULATION: Large high-risk clinical target volume (HR-CTV) volume (>40 ml) at the time of brachytherapy cervical cancer patients were recruited. METHODS: This study is a retrospective analysis of 76 patients with locally advanced cervical cancer (FIGO IIB-IVA) treated with concurrent chemoradiotherapy followed by IC/IMRT between June 2010 and October 2016. External radiotherapy (45 Gy in 25 fractions) was adminstered with cisplatin chemotherapy treatment before IC/IMRT. The IMRT plan was optimised using the ICBT plan base dose plan by an inverse dose optimisation tool which allows the use of DVH constraints on the total dose of ICBT. A seven-field gantry angle IMRT plan was devised to avoid hotspots when optimising the boost plan. The prescription dose for HR-CTV and IR-CTV were 6 and 5 Gy per fraction for five fractions, respectively. RESULTS: Mean HR-CTV was 65.8 ± 23.6 ml at the time of brachytherapy. D90 for HR-CTV and IR-CTV were 88.7 ± 3.6 Gy and 78.1 ± 2.5 Gy. D2cc for bladder, rectum, sigmoid and small intestine were 71.8 ± 3.8, 64.6 ± 4.9, 63.9 ± 5.3 and 56.7 ± 8.7 Gy, respectively. Median follow-up was 85 months (47.9-124.2 months). Five-year local recurrence-free survival rate, metastasis recurrence-free survival rate, disease-free survival rate and cancer-special survival rate were 87.6, 82.4, 70.9 and 76.3%, respectively. The grade 1 + 2 gastrointestinal and urinary late toxicities were 15.8 and 21.1%, and grade 3 late toxicities were 3.9 and 5.2%, respectively. Neither acute nor late grade 4 gastrointestinal or urinary toxicities were seen. CONCLUSIONS: The combination of ICBT with an applicator-guided supplementary IMRT boost achieved excellent local control and overall survival with low toxicity for bulky residual cervical tumour.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lu S, Wang S, Kim RY, et al. Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour. BJOG. 2022. PMID: 36330947. doi:10.1111/1471-0528.17340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。